In a filing, Ionis Pharmaceuticals Inc revealed its EVP, Chief Human Resources Ofc Devers Shannon L. unloaded Company’s shares for reported $0.32 million on Jan 22 ’26. In the deal valued at $81.34 per share,3,977 shares were sold. As a result of this transaction, Devers Shannon L. now holds 22,541 shares worth roughly $1.81 million.
Then, Devers Shannon L. bought 3,977 shares, generating $323,490 in total proceeds.
Before that, Baroldi Mariana bought 1,171 shares. Ionis Pharmaceuticals Inc shares valued at $93,680 were divested by the Member of immediate family of at a price of $80.00 per share.
JP Morgan upgraded its Ionis Pharmaceuticals Inc [IONS] rating to an Overweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in late September from “a Sell” to “a Neutral”. BMO Capital Markets also remained covering IONS and has increased its forecast on September 03, 2025 with a “an Outperform” recommendation from previously “Market perform” rating. Morgan Stanley revised its rating on July 31, 2025. It rated IONS as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of IONS
On Friday, Ionis Pharmaceuticals Inc [NASDAQ:IONS] saw its stock fall -1.84% to $80.29. Over the last five days, the stock has gained 3.98%. Ionis Pharmaceuticals Inc shares have risen nearly 147.03% since the year began. Nevertheless, the stocks have risen 1.49% over the past one year.
How much short interest is there in Ionis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Ionis Pharmaceuticals Inc stocks on 2025-12-31, dropping by -0.74 million shares to a total of 14.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 15.63 million shares. There was a decline of -4.98%, which implies that there is a negative sentiment for the stock.
